Checkpoint Therapeutics Inc (NASDAQ: CKPT) is 25.00% higher on its value in year-to-date trading and has touched a low of $1.38 and a high of $4.50 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The CKPT stock was last observed hovering at around $3.98 in the last trading session, with the day’s gains setting it 0.02%.
Currently trading at $4.00, the stock is 32.00% and 27.28% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 10.33 million and changing 0.50% at the moment leaves the stock 43.18% off its SMA200. CKPT registered 84.33% gain for a year compared to 6-month gain of 90.48%.
The stock witnessed a 21.58% loss in the last 1 month and extending the period to 3 months gives it a -4.08%, and is 52.09% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 5.27% over the week and 6.67% over the month.
Checkpoint Therapeutics Inc (CKPT) has around 23 employees, a market worth around $195.33M and $0.05M in sales. Profit margin for the company is -98868.09%. Distance from 52-week low is 189.86% and -11.11% from its 52-week high.
The EPS is expected to grow by 72.34% this year, but quarterly earnings will post -100.00% year-over-year. Quarterly sales are estimated to shrink -100.00% in year-over-year returns.
Checkpoint Therapeutics Inc (CKPT) Top Institutional Holders
The shares outstanding are 45.10M, and float is at 35.93M with Short Float at 20.85%.
Checkpoint Therapeutics Inc (CKPT) Insider Activity
The most recent transaction is an insider sale by Oliviero James F III, the company’s CEO, President and Director. SEC filings show that Oliviero James F III sold 10,331 shares of the company’s common stock on Feb 10 ’25 at a price of $3.15 per share for a total of $32543.0. Following the sale, the insider now owns 3.78 million shares.
Checkpoint Therapeutics Inc disclosed in a document filed with the SEC on Feb 07 ’25 that Oliviero James F III (CEO, President and Director) sold a total of 9,233 shares of the company’s common stock. The trade occurred on Feb 07 ’25 and was made at $3.41 per share for $31485.0. Following the transaction, the insider now directly holds 3.79 million shares of the CKPT stock.
Still, SEC filings show that on Feb 06 ’25, GRAY WILLIAM GARRETT (Chief Financial Officer) disposed off 74,110 shares at an average price of $3.67 for $0.27 million. The insider now directly holds 1,458,644 shares of Checkpoint Therapeutics Inc (CKPT).
